

Olmesartan Medoxomil (Olmetec[®])

(No. 78/03)

Sankyo Pharma UK Ltd

Summary of Recommendation

10 November, 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

Advice: following a full submission.

Accepted for restricted use within NHS Scotland.

Olmesartan has been shown to be at least as effective as other angiotensin II receptor antagonists (AIIAs) for the treatment of hypertension. It may be considered for use, along with other AIIAs, as an alternative in patients unable to tolerate an ACE inhibitor.

Professor David H Lawson
Chairman